Treatment characteristics and outcomes in lower-risk, non-del(5q) myelodysplastic syndromes: findings from a medical record review in the USA, Canada and Europe.

IF 3 4区医学 Q2 ONCOLOGY

Future oncology Pub Date : 2024-01-01 Epub Date: 2024-08-14 DOI:10.1080/14796694.2024.2379228

Maria Diez-Campelo, Aylin Yucel, Ravi K Goyal, Rohan C Parikh, Elizabeth Esterberg, Maria Jimenez, Martina Sluga-O'Callaghan, Dimana Miteva, Hong Xiao, Ulrich Germing

{"title":"Treatment characteristics and outcomes in lower-risk, non-del(5q) myelodysplastic syndromes: findings from a medical record review in the USA, Canada and Europe.","authors":"Maria Diez-Campelo, Aylin Yucel, Ravi K Goyal, Rohan C Parikh, Elizabeth Esterberg, Maria Jimenez, Martina Sluga-O'Callaghan, Dimana Miteva, Hong Xiao, Ulrich Germing","doi":"10.1080/14796694.2024.2379228","DOIUrl":null,"url":null,"abstract":"Aim: To assess treatment patterns and outcomes in patients with non-del(5q) lower-risk myelodysplastic syndromes.Methods: Patient medical records were reviewed in the USA, Canada (CAN), UK and the EU.Results: Analysis included 119 patients in the USA/CAN (median age, 61.5 years) and 245 patients in the UK/EU (median age, 67.3 years). Most patients received erythropoiesis-stimulating agents (ESAs) as first-line (1L) therapy (USA/CAN: 89.0%; UK/EU: 90.2%). A substantial proportion of 1L erythropoiesis-stimulating agent-treated patients were transfusion dependent before 1L (USA/CAN: 37.1%; UK/EU: 51.2%); a small percentage of these patients achieved transfusion independence during 1L therapy (USA/CAN: 2.8%; UK/EU: 14.4%).Conclusion: These findings highlight an unmet need for more effective treatments among patients with non-del(5q) lower-risk myelodysplastic syndromes.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":null,"pages":null},"PeriodicalIF":3.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11497946/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2024.2379228","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/14 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: To assess treatment patterns and outcomes in patients with non-del(5q) lower-risk myelodysplastic syndromes.Methods: Patient medical records were reviewed in the USA, Canada (CAN), UK and the EU.Results: Analysis included 119 patients in the USA/CAN (median age, 61.5 years) and 245 patients in the UK/EU (median age, 67.3 years). Most patients received erythropoiesis-stimulating agents (ESAs) as first-line (1L) therapy (USA/CAN: 89.0%; UK/EU: 90.2%). A substantial proportion of 1L erythropoiesis-stimulating agent-treated patients were transfusion dependent before 1L (USA/CAN: 37.1%; UK/EU: 51.2%); a small percentage of these patients achieved transfusion independence during 1L therapy (USA/CAN: 2.8%; UK/EU: 14.4%).Conclusion: These findings highlight an unmet need for more effective treatments among patients with non-del(5q) lower-risk myelodysplastic syndromes.

查看原文本刊更多论文

低风险、非del(5q)骨髓增生异常综合征的治疗特点和结果：美国、加拿大和欧洲的病历审查结果。

目的：评估非del(5q)低风险骨髓增生异常综合征患者的治疗模式和疗效。方法：对美国、加拿大、英国和美国的患者病历进行审查：查阅美国、加拿大、英国和欧盟的患者病历。结果分析包括美国/加拿大的 119 名患者（中位年龄 61.5 岁）和英国/欧盟的 245 名患者（中位年龄 67.3 岁）。大多数患者接受红细胞生成刺激剂（ESAs）作为一线（1L）疗法（美国/加拿大：89.0%；英国/欧盟：90.2%）。在接受 1L 红细胞生成刺激剂治疗的患者中，有相当一部分在接受 1L 治疗前依赖输血（美国/加拿大：37.1%；英国/欧盟：51.2%）；其中一小部分患者在接受 1L 治疗期间实现了独立输血（美国/加拿大：2.8%；英国/欧盟：14.4%）。结论这些发现凸显了非del(5q)低风险骨髓增生异常综合征患者对更有效治疗的需求尚未得到满足。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.